



August 08, 2025

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Press Release on Unaudited Financial Results for the quarter ended June 30, 2025**

With reference to the captioned subject; we, Zota Health Care Limited are forwarding herewith enclosed a copy of press release on Unaudited Financial Results for the quarter ended June 30, 2025.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
**Place:** Surat

Encl: Press Release

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

**Zota Health Care Limited Delivers Strong Q1FY26 Performance with 84% YoY Revenue Growth**

*Q1FY26 Consolidated Revenues Grew to ₹ 10,358 lakhs: 84% YoY growth; EBITDA Turned Positive to ₹ 483 lakhs.*

*DavalIndia Networks Expands to 1,745 Stores Nationwide*

**Surat, 8<sup>th</sup> August 2025:**

Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the First Quarter ended 30<sup>th</sup> June 2025.

**Q1FY26 Business Highlights:**

Particulars	Q1FY26			Q1FY25		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of DavalIndia stores*	986	759	1745	387	645	1032
Quarterly Footfall (lakhs)	22.95	12.4	35.35	8.6	8.9	17.5
Quarterly GMV (₹ lakhs)	₹ 5,290	₹ 3,488	₹ 8,778	₹ 2,050	₹ 2,608	₹ 4,658
Average wallets spend (₹)	₹ 231	₹ 281		₹ 238	₹ 290	

*As on 30<sup>th</sup> June 2025*

**Key Operational & Financial Highlights:**

- Consolidated Revenue from operation stood at ₹ 10,358 lakhs in Q1FY26 an increase of 84% YoY from ₹ 5,630 lakhs in Q1FY25.
- Consolidated Gross Profit stood at ₹ 5,845 lakhs compared to ₹ 2,996 lakhs during Q1FY25, a significant increase of 95%.
- Consolidated EBITDA turned positive in Q1FY26 to ₹ 483 lakhs.
- Added 163 new stores during Q1FY26 with 134 COCO & 29 FOFO stores.
- DavalIndia Networks Expands to 1,745 Stores Nationwide.
- Zota Group Appoints Renowned Actor and Entrepreneur Mr. Suniel Shetty as Brand Ambassador

**Commenting on the Q1FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said,**

*"We are pleased to report a strong start to FY26, with Zota Health Care delivering an impressive 84% year-on-year consolidated revenue growth in Q1. This performance was driven by robust demand for affordable generics and our continued efforts to expand access across the country. The growing prevalence of diabetes, cardiovascular diseases, and respiratory disorders remains a key driver of demand for cost-effective medicines. Additionally, the rise of e-pharmacies is significantly improving accessibility in remote areas, supporting last-mile delivery and broadening the reach.*

*During the quarter, we added 163 new stores, including 134 COCO and 29 FOFO outlets. COCO stores grew significantly from 387 to 986 on YoY, strengthening our company-owned infrastructure, while FOFO stores increased from 645 to 759 on YoY, supporting our asset-light expansion strategy. Quarterly footfalls more than doubled to 35.35 lakhs, up from 17.5 lakhs in Q1 FY25, fuelled by our aggressive store expansion strategy and growing brand awareness. To further boost brand visibility and consumer engagement, we appointed renowned actor and entrepreneur Mr. Suniel Shetty as our Brand Ambassador during the quarter. This surge in footfall translated into an 88% increase in (GMV), which rose to ₹8,778 lakhs from ₹4,658 lakhs in the same period last year. Notably, this growth was well-distributed across both COCO and FOFO formats.*

*Looking ahead, we remain committed to sustaining this momentum by deepening our national footprint and enhancing store-level efficiencies. Our growth strategy is well-aligned with the evolving trends in the Indian generics market, and we are well-positioned to capitalize on the rising demand for affordable, high-quality medicines across the country.”*

**About Zota Health Care Limited:**

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: [www.zotahealthcare.com](http://www.zotahealthcare.com)

**For details please contact:**

<b>Mr. Ashvin Variya</b>	<b>Mr. Siddesh Chawan</b>	<b>Mr. Ajit Mishra</b>
CS, Zota Health Care Ltd	Ernst & Young LLP, Investor Relations	Ernst & Young LLP, Investor Relations
E: <a href="mailto:cszota@zotahealthcare.com">cszota@zotahealthcare.com</a>	E: <a href="mailto:Siddesh.Chawan@in.ey.com">Siddesh.Chawan@in.ey.com</a>	E: <a href="mailto:Ajit.J.Mishra@in.ey.com">Ajit.J.Mishra@in.ey.com</a>

**Disclaimer:** Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.